Considering that EGFR is overexpressed in 40–89% of NSCLC (160) and 5–30% of breast cancer tumors (161, 162), the described scenario places EGFR as a candidate for therapeutic strategies that combine EGFR and ROR1 CAR-T cells. This evidence concerns the gene ROR1 and non-small cell lung carcinoma.